Used in pharmaceutical research as a potent cereblon E3 ligase modulator. It functions as a key intermediate in the synthesis of targeted protein degraders, including PROTACs (proteolysis-targeting chimeras), which are designed to degrade disease-causing proteins. Shows activity in oncology studies, particularly in hematological malignancies, due to its ability to induce degradation of transcription factors involved in cancer cell proliferation. Also explored for immunomodulatory effects and potential use in treating inflammatory and autoimmune conditions. Its structural features enable high binding affinity to cereblon, making it valuable in developing novel therapeutics with improved selectivity and potency.